Back

VJHemOnc is committed to improving our service to you

iwNHL 2015 | iwNHL 2015 roundtable: Day 2 highlights – ibrutinib for diffuse large B-cell lymphoma

VJHemOnc is committed to improving our service to you

John Gribben and Wyndham Wilson

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, on highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They discuss how improved understanding of B-cell biology may be used to inform treatment decisions, including targeting B-cell receptor signaling with ibrutinib for the treatment of patients with diffuse large B-cell lymphoma.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter